D-0246-2021 Class II Terminated
FDA drug recall D-0246-2021 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Jan 8, 2021 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Sep 7, 2023). Affected quantity: 44,256 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 10, 2021
- Initiation Date
- Jan 8, 2021
- Termination Date
- Sep 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 44,256 bottles
Product description
Nortriptyline HCl Capsules, USP equivalent to 10mg base Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532 NDC 51672-4001-1
Reason for recall
CGMP deviations.
Distribution pattern
Nationwide
Code information
AC05096, AC05098, and AC05099; Exp 10/31/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0246-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026